Phase II study of tepotinib in NSCLC patients with METex14 mutations.-MedSci.cn

Phase II study of tepotinib in NSCLC patients with METex14 mutations.

Paik, PK; Veillon, R; Cortot, AB; Felip, E; Sakai, H; Mazieres, J; Griesinger, F; Horn, L; Senellart, H; Van Meerbeeck, JP; Carpeno, JD; Patel, JD; Garassino, MC; Morise, M; Reinmuth, N; Viteri, S; Tokito, T; Sakamoto, T; Scheele, J; Le, XN

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务